# JMCR Partners

> JMCR Partners is a VC fund in Hong Kong backing Biotechnology and Health Care. See 23 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Hong Kong, Hong Kong
- Total investments: 23
- Last investment: Jul 2020
- Lead investor: 74%
- Fund size: $74M
- Last fund: Aug 2018
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/jmcr-partners/
- Website: http://www.jmcrpartners.com/
- Facebook: https://www.facebook.com/JMCR-Partners-102851133906603/

JMCR Partners is a venture capital firm based in Shanghai, China and was founded in 2013. The firm seeks to invest in the biotechnology and healthcare sectors. JMCR family office was established in 2013, founded to manage the private assets for founder‘s family and close relations，including 隽华资本 JMCR Capital ® , 隽华国际 JMCR Partners ® and JMRE.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 35% |
| Health Care | 6 | 26% |
| Medical | 3 | 13% |
| Pharmaceutical | 3 | 13% |
| Therapeutics | 2 | 9% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 9 | 39% |
| Seed | 3 | 13% |
| Series B | 3 | 13% |
| Series C | 3 | 13% |
| Funding Round | 2 | 9% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 10 | 43% |
| China | 3 | 13% |
| Belgium | 1 | 4% |
| Switzerland | 1 | 4% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Clues Therapeutics Inc. | Integrate multi-technology target screening and drug discovery to improve innovation development efficiency. | $1.3M | Convertible Note | Jul 20, 2020 |  |
| Anji Pharmaceuticals | Anji Pharmaceuticals is focused on tackling high-value targets validated by human genetics. We are exhaustive in our discovery and clinical efforts while nimble in our strategy and execution. We have assembled a world-class team of scientist entrepreneurs who are committed to accelerate innovative medicines in China and worldwide. | $12M | Series A | Jul 01, 2020 |  |
| Diagon, Inc. | Technology for generation and transplantation of Human Islet-like organoids. | $5M | Convertible Note | May 18, 2020 |  |
| Proviva Therapeutics, Inc | Prodrug design platform for cytokines and other fusion proteins |  | Seed | Jan 02, 2020 |  |
| VivaVision Biotech | VivaVision Biotech is a clinical-stage R&D biopharmaceutical company. | $9.2M | Series C | Sep 26, 2019 |  |
| Anji Pharmaceuticals | Anji Pharmaceuticals is focused on tackling high-value targets validated by human genetics. We are exhaustive in our discovery and clinical efforts while nimble in our strategy and execution. We have assembled a world-class team of scientist entrepreneurs who are committed to accelerate innovative medicines in China and worldwide. | $14M | Series A | Jun 28, 2019 |  |
| Riparian Pharmaceuticals | Riparian Pharmaceuticals is an early stage biotechnology company employing innovative models of vascular pathophysiology to discover novel therapeutics. The company develops medical therapies designed to treat cardiovascular and inflammatory diseases. The company is based in Boston Massachusetts. | $3M | Series A | Oct 12, 2018 |  |
| Clues Therapeutics Inc. | Integrate multi-technology target screening and drug discovery to improve innovation development efficiency. | $800K | Seed | Sep 10, 2018 |  |
| SQZ Biotech | SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cellengineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges. | $72M | Series C | Aug 08, 2018 |  |
| Tekeluo Biotech | Tekeluo Biotech is a Healthcare company. | $4.5M | Series A | Aug 01, 2018 |  |

10 of 23 investments shown.

## Co-investors
- Viva Ventures Biotech Fund — VC Fund, 19 deals together
- [Viva BioInnovator](https://shizune.co/investors/profile/viva-biotech) — VC Fund, 4 deals together
- Beida Biomedical Industry Fund — VC Fund, 2 deals together
- [City Hill Ventures](https://shizune.co/investors/profile/city-hill-ventures) — VC Fund, 2 deals together
- [Ming Bioventures](https://shizune.co/investors/profile/ming-bioventures) — VC Fund, 2 deals together
- Yingqi Investment — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does JMCR Partners invest in?

JMCR Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Seed stage. Most of the 23 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did JMCR Partners last invest?

The most recent investment recorded for JMCR Partners closed in Jul 2020. Shizune tracks 23 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co